ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

ViaCyte CEO Paul Laikind holds two thin capsules, one for humans, another for lab mice, that contain insulin-producing cells. The therapy could significantly alter the quality of life for people with type 1 diabetes.

— Johnson & Johnson is joining forces with San Diego-based ViaCyte Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129